Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China

Table 3 one-way sensitivity analysis results

ICER(Cost/QALY)	one-way sensitivity analysis
Basic analysis	5548.07
PwarST Adjust to maximum	5112.44
PwarST Adjust to minimum	8176.64
PwarICH Adjust to maximum	4470.03
PwarICH Adjust to minimum	6189.53
Umin Adjust to maximum	4645.53
Umin Adjust to minimum	6058.70
Cost of rivaroxaban Adjust to maximum	9281.03
Cost of rivaroxaban Adjust to minimum	4311.95

ICER incremental cost-effectiveness ration; PwarST Risk of cerebral infarction with warfarin; PwarICH Risk of intracranial hemorrhage with warfarin; Umin Quality of life adjusted years in patients with mild dysfunction

ISSN: 1472-6963